Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T35173
|
||||
Former ID |
TTDI02026
|
||||
Target Name |
Inhibitor of apoptosis protein 1
|
||||
Gene Name |
BIRC3
|
||||
Synonyms |
API2; Apoptosis inhibitor 2; Baculoviral IAP repeatcontaining protein3; CIAP2; IAP homolog C; IAP1; RING finger protein 49; TNFR2TRAFsignaling complex protein 1; hIAP1; BIRC3
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86] | ||||
Function |
Multi-functional protein which regulatesnot only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin- protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin- protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase- independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8.
|
||||
BioChemical Class |
Carbon-nitrogen ligase
|
||||
UniProt ID | |||||
EC Number |
EC 6.3.2.-
|
||||
Sequence |
MNIVENSIFLSNLMKSANTFELKYDLSCELYRMSTYSTFPAGVPVSERSLARAGFYYTGV
NDKVKCFCCGLMLDNWKRGDSPTEKHKKLYPSCRFVQSLNSVNNLEATSQPTFPSSVTNS THSLLPGTENSGYFRGSYSNSPSNPVNSRANQDFSALMRSSYHCAMNNENARLLTFQTWP LTFLSPTDLAKAGFYYIGPGDRVACFACGGKLSNWEPKDNAMSEHLRHFPKCPFIENQLQ DTSRYTVSNLSMQTHAARFKTFFNWPSSVLVNPEQLASAGFYYVGNSDDVKCFCCDGGLR CWESGDDPWVQHAKWFPRCEYLIRIKGQEFIRQVQASYPHLLEQLLSTSDSPGDENAESS IIHFEPGEDHSEDAIMMNTPVINAAVEMGFSRSLVKQTVQRKILATGENYRLVNDLVLDL LNAEDEIREEERERATEEKESNDLLLIRKNRMALFQHLTCVIPILDSLLTAGIINEQEHD VIKQKTQTSLQARELIDTILVKGNIAATVFRNSLQEAEAVLYEHLFVQQDIKYIPTEDVS DLPVEEQLRRLQEERTCKVCMDKEVSIVFIPCGHLVVCKDCAPSLRKCPICRSTIKGTVR TFLS |
||||
Drugs and Mode of Action | |||||
Pathways | |||||
KEGG Pathway | NF-kappa B signaling pathway | ||||
Ubiquitin mediated proteolysis | |||||
Apoptosis | |||||
Focal adhesion | |||||
NOD-like receptor signaling pathway | |||||
TNF signaling pathway | |||||
Toxoplasmosis | |||||
Pathways in cancer | |||||
Transcriptional misregulation in cancer | |||||
Small cell lung cancer | |||||
NetPath Pathway | IL5 Signaling Pathway | ||||
IL1 Signaling Pathway | |||||
IL2 Signaling Pathway | |||||
TNFalpha Signaling Pathway | |||||
Notch Signaling Pathway | |||||
TCR Signaling Pathway | |||||
PANTHER Pathway | Apoptosis signaling pathway | ||||
CCKR signaling map ST | |||||
Pathway Interaction Database | CD40/CD40L signaling | ||||
FAS (CD95) signaling pathway | |||||
TNF receptor signaling pathway | |||||
Ceramide signaling pathway | |||||
p75(NTR)-mediated signaling | |||||
C-MYB transcription factor network | |||||
Negative effector of Fas and TNF-alpha | |||||
Caspase Cascade in Apoptosis | |||||
Reactome | NOD1/2 Signaling Pathway | ||||
RIPK1-mediated regulated necrosis | |||||
Regulation of TNFR1 signaling | |||||
TNFR1-induced NFkappaB signaling pathway | |||||
TNFR2 non-canonical NF-kB pathway | |||||
Regulation of necroptotic cell death | |||||
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | |||||
IKK complex recruitment mediated by RIP1 | |||||
WikiPathways | Focal Adhesion | ||||
Apoptosis | |||||
TNF alpha Signaling Pathway | |||||
TWEAK Signaling Pathway | |||||
Apoptosis Modulation and Signaling | |||||
References | |||||
Ref 532581 | Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.